UPDATED AUGUST 31 // The first T-cell therapy that uses chimeric antigen receptor (CAR) technology has been approved today by the US Food and Drug Administration (FDA), paving the way for the other products using this novel approach that are in development. "We're entering a new frontier ...
ABU DHABI, UAE – December 19, 2024 –For the first time in the Middle East, Abu Dhabi Stem Cells Center (ADSCC) has successfully performed Chimeric Antigen Receptor T-Cell Therapy (CAR-T) for a patient with systemic lupus erythematosus (SLE), marking a major step forward in personalized ...
making it the first approved chimeric antigen receptor (CAR) T-cell therapy for the treatment of adult patients with relapsed or refractorymantle cell lymphoma(MCL) in the European Union.
BMS’ Abecma Becomes First CAR T Cell Therapy Approved in the EU for Triple-Class Exposed Relapsed and Refractory Multiple Myeloma
This is the second type of autoimmune disease that physicians and researchers at the Deutsches Zentrum Immuntherapie (DZI) at Universitätsklinikum Erlangen have successfully treated using CAR T-cell therapy. In the first instance, the cells excelled in treating systemic lupus erythematosus (SLE)....
CELLULAR therapyMONOCLONAL antibodiesPATIENT safetyT cellsTREATMENT effectivenessIn the phase I ALPHA trial, the first allogeneic "off‐the‐shelf" CAR T‐cell therapy regimen showed clinical benefits in patients with relapsed/refractory large B‐cell or follicular lymphoma...
Johnson & Johnson’s Janssen unit has filed for approval of its multiple myeloma CAR-T ciltacabtagene autoleucel in Europe, chasing after a rival therapy from Bristol-Myers Squibb. The BCMA-targeting CAR-T – also known as cilta-cel – has been filed wi
The FDA gave the green light to Novartis's tisagenlecleucel for the treatment of acute lymphoblastic leukaemia (ALL), marking a historic approval for a first-in-modality chimeric antigen receptor (CAR) T cell therapy. CAR Ts are an ex vivo form of gene therapy, in which T cells are rem...
Dr. Krickau had come to the end of the line as far as treatment options were concerned. "I have nothing left to give her"—this is what Dr. Krickau said to the team at the Pediatric Oncology department when he approached them with the idea of trying CAR-T cell therapy. "Up to now...
本次收购建立在罗氏与Poseida现有合作的基础之上。双方于2022年签署合作与许可协议，共同致力于开发现货型CAR-T细胞疗法，以满足血液恶性肿瘤患者的未满足医疗需求。参考资料：[1] Roche enters into a definitive agreement to acquire PoseidaTherapeutics, including cell therapy candidates and related platformtechnologies...